R Hamood1, H Hamood2,3, I Merhasin4, L Keinan-Boker1,5. 1. School of Public Health, University of Haifa, Haifa, Israel. 2. School of Public Health, University of Haifa, Haifa, Israel. hhamood@leumit.co.il. 3. Leumit Health Services, Haharoshet 13, Karmiel, Israel. hhamood@leumit.co.il. 4. Leumit Health Services, Netanya, Israel. 5. Ministry of Health, Israel Center for Disease Control, Ramat Gan, Israel.
Abstract
The long-term impact of hormone therapy for breast cancer on risk of osteoporosis and the extent to which bone screening recommendations are implemented in daily practice remain unknown. We found that the aromatase inhibitor-induced risk of osteoporosis did not continue in the off-treatment follow-up. Adherence to screening recommendations was suboptimal. INTRODUCTION: A case-cohort study was undertaken to better understand the impact of hormone therapy on breast cancer patients' risk of osteoporosis, and to estimate the extent to which current bone mineral density screening recommendations are implemented in real-life daily practice. METHODS: This study is based on 1692 female breast cancer survivors recruited from "Leumit" healthcare fund, who were diagnosed with primary nonmetastatic invasive breast cancer between 2002 and 2012. A 20% random subcohort was sampled at baseline, and all osteoporosis cases were identified. Adjusted hazard ratios (HR) with 95% confidence intervals (CI) were estimated by weighted Cox proportional hazards models. RESULTS: Of 1692 breast cancer survivors, 312 developed osteoporosis during a median follow-up of 5 years. The crude cumulative incidence of osteoporosis accounting for death as a competing risk was 25.7% (95% CI, 21.9-29.5%). In multivariable analyses, osteoporosis was positively associated with the aromatase inhibitor (AI) sequential treatment after tamoxifen (HR, 3.14; 95% CI, 1.44-6.88; P = .004) but was more pronounced with AI use as upfront monotherapy (HR, 5.53; 95% CI, 1.46-20.88; P = .012). This effect did not continue in the off-treatment follow-up. In subgroup analysis by menopausal status, tamoxifen did not seem to confer a protective effect on bone health in postmenopausal patients. Adherence to screening recommendations in AI-treated postmenopausal women was suboptimal, particularly at baseline and after 48 months of continuous AI use. CONCLUSIONS: The natural, age-related reduction in bone density is exacerbated by breast cancer active AI treatment. Future research should focus on investigating screening adherence-related barriers/facilitators and effective strategies to bring practice in line with agreed standards.
The long-term impact of hormone therapy for breast cancer on risk of osteoporosis and the extent to which bone screening recommendations are implemented in daily practice remain unknown. We found that the aromatase inhibitor-induced risk of osteoporosis did not continue in the off-treatment follow-up. Adherence to screening recommendations was suboptimal. INTRODUCTION: A case-cohort study was undertaken to better understand the impact of hormone therapy on breast cancerpatients' risk of osteoporosis, and to estimate the extent to which current bone mineral density screening recommendations are implemented in real-life daily practice. METHODS: This study is based on 1692 female breast cancer survivors recruited from "Leumit" healthcare fund, who were diagnosed with primary nonmetastatic invasive breast cancer between 2002 and 2012. A 20% random subcohort was sampled at baseline, and all osteoporosis cases were identified. Adjusted hazard ratios (HR) with 95% confidence intervals (CI) were estimated by weighted Cox proportional hazards models. RESULTS: Of 1692 breast cancer survivors, 312 developed osteoporosis during a median follow-up of 5 years. The crude cumulative incidence of osteoporosis accounting for death as a competing risk was 25.7% (95% CI, 21.9-29.5%). In multivariable analyses, osteoporosis was positively associated with the aromatase inhibitor (AI) sequential treatment after tamoxifen (HR, 3.14; 95% CI, 1.44-6.88; P = .004) but was more pronounced with AI use as upfront monotherapy (HR, 5.53; 95% CI, 1.46-20.88; P = .012). This effect did not continue in the off-treatment follow-up. In subgroup analysis by menopausal status, tamoxifen did not seem to confer a protective effect on bone health in postmenopausal patients. Adherence to screening recommendations in AI-treated postmenopausal women was suboptimal, particularly at baseline and after 48 months of continuous AI use. CONCLUSIONS: The natural, age-related reduction in bone density is exacerbated by breast cancer active AI treatment. Future research should focus on investigating screening adherence-related barriers/facilitators and effective strategies to bring practice in line with agreed standards.
Entities:
Keywords:
Aromatase inhibitor; Bone health; Breast cancer; Osteoporosis; Survivorship; Tamoxifen
Authors: Betty A Mincey; Mei Sheng Duh; Simu K Thomas; Erick Moyneur; Maryna Marynchencko; Simone Peart Boyce; David Mallett; Edith A Perez Journal: Clin Breast Cancer Date: 2006-06 Impact factor: 3.225
Authors: Douglas Tremblay; Vaibhav Patel; Kenneth M Fifer; Jessica Caro; Olivia Kolodka; John Mandelli; Charles L Shapiro Journal: Support Care Cancer Date: 2017-07-26 Impact factor: 3.603
Authors: Adam Brufsky; W Graydon Harker; J Thaddeus Beck; Robert Carroll; Elizabeth Tan-Chiu; Christopher Seidler; John Hohneker; Leo Lacerna; Stephanie Petrone; Edith A Perez Journal: J Clin Oncol Date: 2006-12-11 Impact factor: 44.544
Authors: Taylor P Stewart; Mary E Sesto; James E Haine; Mary F Henningfield; Kirsten Norslien; Xiao Zhang; David L Hahn; Amye J Tevaarwerk Journal: J Cancer Educ Date: 2022-02 Impact factor: 2.037
Authors: Komal Waqas; Joana Lima Ferreira; Elena Tsourdi; Jean-Jacques Body; Peyman Hadji; M C Zillikens Journal: J Bone Oncol Date: 2021-03-18 Impact factor: 4.072